What Биопарокс Treats: Main Uses and Benefits

The primary therapeutic focus of this medication, applied as a local spray, is relevant when supportive symptom management is appropriate for symptoms associated with acute episodes in the upper respiratory airways. This includes conditions involving episodic or fluctuating manifestations such as tonsillitis, pharyngitis, laryngitis, rhinitis, and sinusitis. It is applicable within clinical settings that involve acute or disruptive symptom patterns.

The medication is often used during phases when symptoms become more noticeable, such as when symptoms related to physical discomfort or nasal obstruction become more disruptive during flare-ups. It is applied in addressing symptom clusters that may become intense or disruptive and interfere with daily functioning. The overall therapeutic goal is to provide supportive relief that helps ease the overall symptom burden.

Quick Fact: Relief for Acute Symptom Clusters

This treatment contributes to improved comfort during periods of heightened symptoms and supports the patient in managing functional strain associated with irritative states.

The eligibility profile for the use of Bioparox (fusafungine) is determined by an official regulatory action that prohibits its use in major regions. In the European Union (EU) and associated territories, the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) endorsed the revocation of marketing authorizations (MA). This action was based on the conclusion that the medicine’s risks outweighed its benefits for all currently authorized uses.

Consequently, use is not allowed for any population group in these jurisdictions. Absolute contraindications for the product, as stated in official regulatory documents, include patients with known hypersensitivity to the active substance or excipients, a critical factor cited in the regulatory review.

Age-related eligibility rules are highly restrictive: use is explicitly prohibited in children under 12 years of age due to the risk of serious allergic reactions, including bronchospasm. Serious allergic reactions were reported across all age-ranges, leading to the overall restriction on use in adults and older adults as well. The official regulatory classification is Contraindicated with an overall status of MA Revoked, defining the final eligibility structure.

Interactions with other medicines and products

Биопарокс (Fusafungine) is formulated as a nasal and oromucosal spray intended strictly for local topical application in the upper respiratory tract. The official regulatory interaction profile for this medicine is characterized by its local action.

Authoritative government health agencies consistently conclude that systemic absorption of Fusafungine is negligible following local administration. This minimal systemic exposure is the key factor that determines the interaction status of the medicine, eliminating the potential for most systemic drug interactions.

Official Regulatory Interaction Status

Category	Regulatory Status
Contraindicated Combinations	None documented. Official prescribing information does not list any specific products formally prohibited for co-administration due to systemic interaction risk.
Metabolic Interactions (e.g., CYP450)	None documented. No potential for clinically significant interactions involving inhibition or induction of cytochrome P450 enzymes is reported due to negligible systemic exposure.
Exposure Modification	None documented. The drug is not documented to increase or reduce the plasma levels of co-administered systemic medicines.
Timing Requirements	None documented. There are no mandatory time separation rules required between the administration of the spray and other medicinal products.

Official regulatory documents affirm that this structure eliminates the need to document interactions with food, alcohol, herbal products, or specific population subsets (e.g., hepatic impairment). The lack of systemic exposure results in no documented constraints for co-administration.

Биопарокс, whose active component is the cyclohexadepsipeptide fusafungine, exerts its action through two primary mechanistic pathways: direct cellular disruption and immunomodulation. The drug selectively accumulates in the upper respiratory tract mucosa following administration.

Antimicrobial Mechanism

Fusafungine acts as an ionophore, interacting with cell membranes of various microorganisms. This interaction facilitates the transport of alkali cations across the plasma membrane, leading to a disruption of the transmembrane ion gradient and loss of membrane potential. This alteration of the electrochemical balance is thought to interfere with essential cellular processes, resulting in a bacteriostatic effect, which limits microbial proliferation.

Anti-Inflammatory Mechanism

At the cellular level, fusafungine functions as a negative modulator of specific inflammatory pathways within immune cells. It targets activated macrophages and T-lymphocytes, inhibiting their activation and subsequent proliferation. Specifically, the molecule down-regulates the expression of the adhesion molecule ICAM-1 (Intercellular Adhesion Molecule-1) on the cell surface. Concurrently, it acts as an inhibitor of pro-inflammatory cytokine production, including Tumor Necrosis Factor-alpha (TNF-alpha) and Interferon-gamma (IFN-gamma) synthesis by activated T cells. The resulting intracellular cascade suppresses the release of inflammatory mediators, leading to systemic physiological modulation characterized by a localized reduction in cellular infiltration and vascular permeability.

General Principles of Fusafungine Administration

The usage of Fusafungine (marketed as Биопарокс, among other names) involves its application as a topical pressurized spray solution for local delivery to the upper respiratory tract. The route of administration involves use via both the oromucosal route (mouth) and the nasal route (nose) to ensure the active substance reaches the intended localized areas.

Dosing and Administration Schedule

Administration follows a fixed-dose, divided-use pattern with precise instructions regarding the number of puffs for each route. The standard adult regimen requires a specific count of spray applications for each session, conducted at a fixed interval throughout the day.

Population	Dosing Regimen per Session (4 times daily)	Special Use Conditions
Adults	4 puffs into the mouth and 2 puffs into each nostril.	Short-term use, typically 7 days.
Children (over 30 months)	2 puffs into the mouth and/or 1 puff into each nostril.	No dose adjustments required for elderly or those with renal/hepatic impairment.

Administration Technique and Duration

Prior to the very first use, the device requires a priming step where the main actuator must be depressed four times to prepare the valve for consistent dose delivery. During administration, the user must hold the bottle upright and use the specific adapter for either oral or nasal application. The treatment course is defined as a short-term duration, normally lasting seven days. If no improvement is observed after this seven-day course, the use of the product should be discontinued.

Bioparox, which contains the active substance fusafungine, was an aerosol antibiotic and anti-inflammatory agent previously marketed for the treatment of upper respiratory tract infections (URTIs).

Efficacy Data from Research

Studies investigated the efficacy of fusafungine in conditions such as acute rhinopharyngitis and laryngitis. A pooled analysis of three randomized, double-blind, placebo-controlled trials focusing on acute rhinopharyngitis suggested that a higher percentage of patients receiving fusafungine showed an improvement in nasal symptom scores by day four compared to those receiving a placebo.

Research also explored fusafungine's potential to reduce symptom severity in upper respiratory tract infections, with one multi-centre study observing a significant reduction in symptoms from baseline.

Safety Profile and Regulatory Status

Regulatory review by the European Medicines Agency (EMA) concluded that the benefits of fusafungine did not outweigh the risks, particularly concerning the potential for rare but serious allergic reactions, including bronchospasm (severe breathing difficulty). The review also noted that the evidence for beneficial effects was weak and raised concerns regarding the potential for promoting antibiotic resistance.

Following this safety and efficacy review, the EMA recommended the revocation of marketing authorisations for fusafungine-containing sprays in the European Union in 2016. Consequently, the medicine was voluntarily or mandatorily withdrawn from various global markets.

Common questions about Биопарокс (FAQ)

Q: Why was Биопарокс discontinued or withdrawn from the market?

A: The European Medicines Agency (EMA) recommended the withdrawal of the marketing authorization in the European Union because the benefits were not considered to outweigh the risks. Key regulatory concerns included the potential for rare but serious allergic reactions, such as life-threatening bronchospasm (severe breathing difficulty), and concerns regarding the weak evidence of efficacy and the potential for antibiotic resistance.

Q: Are there any known severe allergic reactions associated with Биопарокс?

A: Yes. Official product information describes serious allergic reactions as a known, though rare, risk. These reactions can include Anaphylactic Shock, Bronchospasm (severe breathing difficulty), and Laryngeal Oedema (swelling of the voice box or throat), which may occur shortly after the product's use. Regulatory documents caution that these are the most significant documented safety constraints.

Q: Can pregnant women use Биопарокс?

A: Official regulatory documents indicate that there are no clinical data available concerning the use of the product in pregnant women. While studies in animals did not show direct harmful effects, the documents note that caution is advised regarding use in pregnant women, reflecting the lack of sufficient human safety data.

Q: What are the official guidelines regarding the use of Биопарокс in nursing mothers?

A: Regulatory documents state that it is unknown whether the active substance, Fusafungine, is excreted into human breast milk. Based on the absence of definitive safety data, the product is not recommended for use in breast-feeding women.

Q: Can the product be used by adolescents?

A: Official product labeling contains a definitive contraindication for use in children under 12 years due to the risk of severe allergic and respiratory reactions. For individuals aged 12 years and older, the use falls within the established guidelines for the adult population group.

Q: What is the official regulatory status of Биопарокс?

A: The official regulatory status in many regions changed following the 2016 review by the European Medicines Agency (EMA). The EMA recommended the revocation of marketing authorizations for Fusafungine-containing medicines, which led to the withdrawal of the product from the market in the European Union and subsequent withdrawal from many other global markets.

Q: Does Биопарокс have any interaction with common cold medicines?

A: Regulatory documents state that no specific drug interactions are documented, including with common over-the-counter cold remedies. This is primarily because the medicine is strictly for local application with negligible systemic absorption (meaning very little of the active substance enters the bloodstream).

Q: Can I use Биопарокс if I'm taking other prescription medication?

A: The official regulatory profile concludes that the potential for clinically significant systemic interactions with other medicines, including prescription medication, is minimal or absent. This status is due to the product being intended strictly for local topical use, resulting in negligible systemic absorption of the active substance.

Q: Can I use Биопарокс if I have asthma?

A: Official information notes that the product is associated with a risk of bronchospasm (severe breathing difficulty), which is classified as a serious adverse reaction. The possibility of serious allergic and respiratory reactions is a documented safety constraint associated with the product.

Q: Why do some sources mention its use for sinusitis?

A: Prior to its withdrawal, Fusafungine-containing medicines were authorized in certain countries for the treatment of upper airway infections, which included specific reference to sinusitis (sinus infection), within their national product information.

Q: Does the efficacy of Биопарокс depend on the specific bacteria causing the infection?

A: The active substance, fusafungine, possesses bacteriostatic activity against most micro-organisms commonly associated with respiratory tract infections. However, regulatory review also noted that the efficacy evidence was weak and that no established susceptibility criteria (clinical breakpoints) were determined by European or US authorities.

Q: How quickly should I expect to see an effect from Биопарокс?

A: The treatment is generally recommended for a short-term duration, typically 7 days. Official guidance specifies that if no improvement is observed after the seven-day course, the use of the product should be discontinued. The requirement to discontinue use if no improvement is observed after seven days sets the regulatory timeframe for assessing efficacy.

Q: What happens if a small amount of the spray is swallowed?

A: The product is formulated for local action in the throat and nose. Regulatory data indicates that following local administration, only transient and very low amounts of the active substance may be detected in the blood (plasma). Negligible systemic absorption is the key characteristic of its use.

Q: What is the difference between Биопарокс and a standard throat spray?

A: Биопарокс contains the active substance Fusafungine, which is classified by health authorities as having a dual-action profile: both antibiotic (bacteriostatic) and anti-inflammatory properties. This differs from many standard throat sprays that often contain only local antiseptics or pain relievers.

Q: Can people with high blood pressure use Биопарокс?

A: Official regulatory documents do not list high blood pressure as a contraindication or precaution for the use of the product. This is consistent with the product's classification as a topical treatment that exhibits negligible systemic absorption and therefore has minimal impact on systemic conditions.

Q: Can people with diabetes use Биопарокс?

A: The official product labeling does not list diabetes as a contraindication or precaution. Regulatory documents note that the lack of clinically significant systemic absorption means no dose adjustments are required for individuals with systemic conditions like renal or hepatic impairment.

Q: What information is available regarding the long-term safety of Биопарокс?

A: The official documentation cautions that the prolonged use of the anti-infective carries a safety-related risk. This risk is specifically described as the potential for developing a superinfection, which is an infection caused by microorganisms that are resistant to the product.

How to Store and Dispose of Биопарокс?

Storage and disposal requirements for Bioparox (fusafungine) are strictly defined by regulatory documents, focusing on the protection and safe handling of the pressurized container.

Storage Conditions

Requirement	Official Instruction
Temperature	Store at a temperature not exceeding 25 °C; Do not expose above 50 °C.
Protection	Must be protected from direct sunlight.
Container	Keep in the original container and out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired product must be carried out in accordance with local requirements. The official rules strictly prohibit discarding the medicine via wastewater or household waste. Due to its nature as an aerosol, the container must not be pierced or incinerated, even when empty.